Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Income from Continuing Operations of 205991000.0 for Q1 2026, up 84.67% on a QoQ basis from 111548000.0 in Q4 2025, and up 1228.66% year-over-year from 15503712.44 in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 205991000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 1228.66% year-over-year to 205991000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 543945000.0 (up 336.01% YoY) and the FY2025 annual result came in at 313752000.0, up 212.8% from the prior year.
- Income from Continuing Operations was 205991000.0 for Q1 2026 at Alnylam Pharmaceuticals, up from 111548000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 292683000.0 in Q3 2025 and bottomed at 405920000.0 in Q3 2022.
- A 5-year average of 77874176.47 and a median of 83763000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 292.43% — and 2026, when it soared 1228.66%.
- Alnylam Pharmaceuticals' Income from Continuing Operations stood at 207493000.0 in 2022, then surged by 33.55% to 137870000.0 in 2023, then surged by 39.24% to 83763000.0 in 2024, then surged by 233.17% to 111548000.0 in 2025, then soared by 84.67% to 205991000.0 in 2026.
- Business Quant data shows ALNY's Income from Continuing Operations at 205991000.0 in Q1 2026, 111548000.0 in Q4 2025, and 292683000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 205.99 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Sep 30, 2025 | 292.68 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -18.25 Mn |
| Dec 31, 2024 | -83.76 Mn |
| Sep 30, 2024 | -111.57 Mn |
| Jun 30, 2024 | -16.89 Mn |
| Mar 31, 2024 | -65.94 Mn |
| Dec 31, 2023 | -137.87 Mn |
| Sep 30, 2023 | 147.75 Mn |
| Jun 30, 2023 | -276.02 Mn |
| Mar 31, 2023 | -174.10 Mn |
| Dec 31, 2022 | -207.49 Mn |
| Sep 30, 2022 | -405.92 Mn |
| Jun 30, 2022 | -277.40 Mn |
| Mar 31, 2022 | -240.34 Mn |
| Dec 31, 2021 | -258.46 Mn |
| Sep 30, 2021 | -204.51 Mn |
| Jun 30, 2021 | -189.56 Mn |